Studying Cognition in SPG4

Studying Cognition in SPG4 Compared to Healthy Controls

Status

Completed

Phases

Unknown

Study type

Observational

Source

ClinicalTrials.gov

Registry ID

NCT03104088

Enrollment

Registered

2017-04-07

Start date

2017-05-10

Completion date

2017-12-24

Last updated

2020-08-28

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Cognitive Impairment, Hereditary Spastic Paraplegia

Brief summary

Comparing the cognitive levels of patients with SPG4 mutations to healthy controls.

Detailed description

Comparing the cognitive levels of patients with SPG4 mutations to healthy controls by using the CANTAB® and MoCA.

Interventions

DIAGNOSTIC_TESTCANTAB

CANTAB Cognitive Assessment (tablet based cognitive testing from CAMCOG)

DIAGNOSTIC_TESTMOCA

Montreal cognitive assessment (MOCA) in German

Study design

Observational model

CASE_CONTROL

Time perspective

PROSPECTIVE

Eligibility

Sex/Gender

ALL

Age

18 Years to 70 Years

Healthy volunteers

Yes

Inclusion criteria

* Patient with SPG4 with known SPAST-Mutation (patient group) or healthy control * Age 18 to 70 years * Written, informed consent

Exclusion criteria

* Lack of ability for a written, informed consent * Presence of gait disorder or other neurological condition (for healthy controls)

Design outcomes

Primary

Measure	Time frame	Description
Identifying cognitive affected domains by using CANTAB	day 1	Number of SPG4 patients with affections in the examined cognitive domains by using CANTAB

Countries

Germany

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026